Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces a change in its Board of Directors with the departure of Ms. Anat Loewenstein and Ms. Nathalie ...

In a new study published in Science, a Belgian research team explores how genetic switches controlling gene activity define ...

Biopharmaceutical Contract Manufacturing Market Biopharmaceutical Contract Manufacturing Learn how outsourcing trends in biopharma m ...

Fourth quarter earnings per share (diluted) of $1.37, an increase of 34.3% compared to fourth quarter 2023 Fourth quarter net income of $130.1 million Fourth quarter ...

Fourth Quarter 2024 Finalized the International Association of Machinists and Aerospace Workers (IAM) agreement and ...